CLINICAL_TRIALS
research
· 2025-04-15
Clinical Trial Update: TP03HN106 in Patients With Critical Limb Ischemia [Phase 2]
Summary
Phase 2 clinical trial TP03HN106 for critical limb ischemia is currently recruiting, with status indicating ongoing enrollment.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Talengen Institute of Life Sciences, Shenzhen, P.R. China. | Conditions: Critical Limb Ischemia | Phase 2 | Status: RECRUITING